Needham & Company Downgrades Theravance Biopharma (TBPH) to Hold, Following Strategic Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Theravance Biopharma (TBPH) PT Lowered to $7 at Baird
September 16, 2021 8:17 AM EDTBaird analyst Brian Skorney lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $7.00 (from $10.00) while maintaining a Neutral rating.
... MoreTheravance Biopharma (TBPH) PT Lowered to $8 at Cowen
September 15, 2021 3:55 PM EDTCowen analyst Marc Frahm lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $8.00 (from $14.00) while maintaining a Market Perform rating.
The analyst commented, "Theravance announced that the Phase 3 SEQUOIA trial of ampreloxetine in nOH did not demonstrate an impact on the... More



